Skip to main content

Advertisement

SpringerLink
Log in

Low-Grade Gliomas

  • Central Nervous System Malignancies
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Low-grade gliomas (LGG) are uncommon central nervous system (CNS) tumors which often present with seizures and few other neurologic signs or symptoms. Multimodality therapy encompassing surgical resection, radiation therapy (RT), and chemotherapy may provide the best disease-free and overall survival (OS). Each of these treatment modalities plays an important role in the treatment of these tumors. The understanding and management of LGG is evolving as randomized clinical trials have begun to address many questions related to the timing and order of each of the available treatments and their individual and combined effects on progression-free survival (PFS) and OS. Currently, an attempt at surgical resection followed by external beam RT is a typical treatment approach, at least in high-risk patients. Observation with serial brain imaging studies or surgical resection or debulking alone may be acceptable options in patients with low-risk tumors. The role of chemotherapy in either group is less clear, but recent studies have indicated that concurrent chemotherapy with radiation improves PFS and may eventually impact OS. The European Organization for Research and Treatment of Cancer (EORTC) and the Radiation Therapy Oncology Group (RTOG) are currently conducting two large Phase III and Phase II studies, respectively. The studies seek to evaluate the efficacy of radiotherapy and either temozolomide or a combination of procarbazine, vincristine, and lomustine in high-risk LGG patients. Ongoing investigative efforts seek to confirm the predictive value of a number of molecular markers including the loss of chromosomes 1p and 19q and the epigenetic silencing of the methylguanine-DNA methyltransferase (MGMT) gene. Additional smaller clinical trials seek to establish the role of newer targeted therapies including small-molecule tyrosine kinase inhibitors in patients with newly diagnosed and recurrent LGG.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Kleihues P: Pathology and Genetics of Tumours of the Nervous System. Lyon, France: IARC Press; 2000

  2. Central Brain Tumor Registry of the United States 2004: Primary Brain Tumors in the United States, 1997–2001, 2004

  3. Claus EB, Black PM: Survival rates and patterns of care for patients diagnosed with supratentorial low-grade gliomas: data from the SEER program, 1973-2001. Cancer 2006, 106:1358-1363. doi:10.1002/cncr.21733.

    Article  PubMed  Google Scholar 

  4. Ohgaki H, Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J.Neuropathol.Exp.Neurol. 2005, 64:479-489.

    CAS  PubMed  Google Scholar 

  5. Pouratian N, Mut M, Jagannathan J, Lopes MB, Shaffrey ME, Schiff D: Low-grade gliomas in older patients: a retrospective analysis of prognostic factors. J.Neurooncol. 2008, 90:341-350. doi:10.1007/s11060-008-9669-3.

    Article  PubMed  Google Scholar 

  6. DeAngelis LM: Brain tumors. N.Engl.J.Med. 2001, 344:114-123. doi:10.1056/NEJM200101113440207.

    Article  CAS  PubMed  Google Scholar 

  7. Shaw EG, Scheithauer BW, O’Fallon JR: Supratentorial gliomas: a comparative study by grade and histologic type. J.Neurooncol. 1997, 31:273-278. doi:10.1023/A:1005715703598.

    Article  CAS  PubMed  Google Scholar 

  8. Lote K, Egeland T, Hager B, Stenwig B, Skullerud K, Berg-Johnsen J, Storm-Mathisen I, Hirschberg H: Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. J.Clin.Oncol. 1997, 15:3129-3140.

    CAS  PubMed  Google Scholar 

  9. Shaw EG, Wang M, Coons S, Brachman D, Buckner JC, Stelzer K, Barger G, Brown PD, Gilbert MR, Mehta MP: Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: Radiation therapy (RT) versus RT + procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). J Clin Oncol 2008, 26:2008 (May 20 suppl; abstr 2006)

    Google Scholar 

  10. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, Afra D, Cornu P, Bolla M, Vecht C, Karim AB: Prognostic factors for survival in adult patients with cerebral low-grade glioma. J.Clin.Oncol. 2002, 20:2076-2084. doi:10.1200/JCO.2002.08.121.

    Article  PubMed  Google Scholar 

  11. Yeh SA, Ho JT, Lui CC, Huang YJ, Hsiung CY, Huang EY: Treatment outcomes and prognostic factors in patients with supratentorial low-grade gliomas. Br.J.Radiol. 2005, 78:230-235. doi:10.1259/bjr/28534346.

    Article  PubMed  Google Scholar 

  12. Chang EF, Smith JS, Chang SM, Lamborn KR, Prados MD, Butowski N, Barbaro NM, Parsa AT, Berger MS, McDermott MM: Preoperative prognostic classification system for hemispheric low-grade gliomas in adults. J Neurosurg. 2008, 109:817-824. doi:10.3171/JNS/2008/109/11/0817.

    Article  PubMed  Google Scholar 

  13. Schiff D, Brown PD, Giannini C: Outcome in adult low-grade glioma: the impact of prognostic factors and treatment. Neurology 2007, 69:1366-1373. doi:10.1212/01.wnl.0000277271.47601.a1.

    Article  PubMed  Google Scholar 

  14. Ricci PE, Dungan DH: Imaging of low- and intermediate-grade gliomas. Semin.Radiat.Oncol. 2001, 11:103-112. doi:10.1053/srao.2001.21420.

    Article  CAS  PubMed  Google Scholar 

  15. Sasaki M, Kuwabara Y, Yoshida T, Nakagawa M, Fukumura T, Mihara F, Morioka T, Fukui M, Masuda K: A comparative study of thallium-201 SPET, carbon-11 methionine PET and fluorine-18 fluorodeoxyglucose PET for the differentiation of astrocytic tumours. Eur.J.Nucl.Med. 1998, 25:1261-1269. doi:10.1007/s002590050294.

    Article  CAS  PubMed  Google Scholar 

  16. Kros JM, Hop WC, Godschalk JJ, Krishnadath KK: Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 1996, 78:1107-1113. doi:10.1002/(SICI)1097-0142(19960901)78:5<1107::AID-CNCR22>3.0.CO;2-5.

    Article  CAS  PubMed  Google Scholar 

  17. Torp SH, Alsaker M: Ki-67 immunoreactivity, basic fibroblastic growth factor (bFGF) expression, and microvessel density as supplementary prognostic tools in low-grade astrocytomas. An immunohistochemical study with special reference to the reliability of different Ki-67 antibodies. Pathol.Res.Pract. 2002, 198:261-265.

    CAS  PubMed  Google Scholar 

  18. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC: A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006, 66:9852-9861. doi:10.1158/0008-5472.CAN-06-1796.

    Article  CAS  PubMed  Google Scholar 

  19. Ohgaki H: Genetic pathways to glioblastomas. Neuropathology. 2005, 25:1-7. doi:10.1111/j.1440-1789.2004.00600.x.

    Article  PubMed  Google Scholar 

  20. Everhard S, Kaloshi G, Criniere E, Benouaich-Amiel A, Lejeune J, Marie Y, Sanson M, Kujas M, Mokhtari K, Hoang-Xuan K, Delattre JY, Thillet J: MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann.Neurol. 2006, 60:740-743. doi:10.1002/ana.21044.

    Article  CAS  PubMed  Google Scholar 

  21. Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y, Siegal T: Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 2006, 106:1759-1765. doi:10.1002/cncr.21809.

    Article  CAS  PubMed  Google Scholar 

  22. Recht LD, Lew R, Smith TW: Suspected low-grade glioma: is deferring treatment safe? Ann.Neurol. 1992, 31:431-436. doi:10.1002/ana.410310413.

    Article  CAS  PubMed  Google Scholar 

  23. Shaw EG, Berkey B, Coons SW, Bullard D, Brachman D, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta M: Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J.Neurosurg. 2008, 109:835-841. doi:10.3171/JNS/2008/109/11/0835.

    Article  PubMed  Google Scholar 

  24. Keles GE, Lamborn KR, Berger MS: Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J.Neurosurg. 2001, 95:735-745.

    Article  CAS  PubMed  Google Scholar 

  25. Sanai N, Berger MS: Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008, 62:753-764. doi:10.1227/01.neu.0000318159.21731.cf.

    Article  PubMed  Google Scholar 

  26. Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS: Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J.Clin.Oncol. 2008, 26:1338-1345. doi:10.1200/JCO.2007.13.9337.

    Article  PubMed  Google Scholar 

  27. Shaw EG, Scheithauer BW, O’Fallon JR, Davis DH: Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery 1994, 34:577-582. doi:10.1097/00006123-199404000-00002.

    Article  CAS  PubMed  Google Scholar 

  28. Shibamoto Y, Kitakabu Y, Takahashi M, Yamashita J, Oda Y, Kikuchi H, Abe M: Supratentorial low-grade astrocytoma. Correlation of computed tomography findings with effect of radiation therapy and prognostic variables. Cancer 1993, 72:190-195. doi:10.1002/1097-0142(19930701)72:1<190::AID-CNCR2820720134>3.0.CO;2-Y.

    Article  CAS  PubMed  Google Scholar 

  29. Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O, Darcel F, Stenning S, Pierart M, Van GM: Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int.J.Radiat.Oncol.Biol.Phys. 2002, 52:316-324. doi:10.1016/S0360-3016(01)02692-X.

    PubMed  Google Scholar 

  30. van den Bent MJ, Afra D, De Witte O, Ben HM, Schraub S, Hoang-Xuan K, Malmstrom PO, Collette L, Pierart M, Mirimanoff R, Karim AB: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005, 366:985-990. doi:10.1016/S0140-6736(05)67070-5.

    Article  PubMed  Google Scholar 

  31. Janny P, Cure H, Mohr M, Heldt N, Kwiatkowski F, Lemaire JJ, Plagne R, Rozan R: Low grade supratentorial astrocytomas. Management and prognostic factors. Cancer 1994, 73:1937-1945. doi:10.1002/1097-0142(19940401)73:7<1937::AID-CNCR2820730727>3.0.CO;2-G.

    Article  CAS  PubMed  Google Scholar 

  32. Philippon JH, Clemenceau SH, Fauchon FH, Foncin JF: Supratentorial low-grade astrocytomas in adults. Neurosurgery 1993, 32:554-559. doi:10.1097/00006123-199304000-00010.

    Article  CAS  PubMed  Google Scholar 

  33. Shaw E, Arusell R, Scheithauer B, O’Fallon J, O’Neill B, Dinapoli R, Nelson D, Earle J, Jones C, Cascino T, Nichols D, Ivnik R, Hellman R, Curran W, Abrams R: Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J.Clin.Oncol. 2002, 20:2267-2276. doi:10.1200/JCO.2002.09.126.

    Article  CAS  PubMed  Google Scholar 

  34. Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, Mascarenhas F, Horiot JC, Parvinen LM, van Reijn M, Jager JJ, Fabrini MG, van Alphen AM, Hamers HP, Gaspar L, Noordman E, Pierart M, van Glabbeke M: A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int.J.Radiat.Oncol.Biol.Phys. 1996, 36:549-556. doi:10.1016/S0360-3016(96)00352-5.

    CAS  PubMed  Google Scholar 

  35. Eyre HJ, Crowley JJ, Townsend JJ, Eltringham JR, Morantz RA, Schulman SF, Quagliana JM, al-Sarraf M: A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J.Neurosurg. 1993, 78:909-914.

    Article  CAS  PubMed  Google Scholar 

  36. Pace A, Vidiri A, Galie E, Carosi M, Telera S, Cianciulli AM, Canalini P, Giannarelli D, Jandolo B, Carapella CM: Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann.Oncol. 2003, 14:1722-1726. doi:10.1093/annonc/mdg502.

    Article  CAS  PubMed  Google Scholar 

  37. Quinn JA, Reardon DA, Friedman AH, Rich JN, Sampson JH, Provenzale JM, McLendon RE, Gururangan S, Bigner DD, Herndon JE, Avgeropoulos N, Finlay J, Tourt-Uhlig S, Affronti ML, Evans B, Stafford-Fox V, Zaknoen S, Friedman HS: Phase II trial of temozolomide in patients with progressive low-grade glioma. J.Clin.Oncol. 2003, 21:646-651. doi:10.1200/JCO.2003.01.009.

    Article  CAS  PubMed  Google Scholar 

  38. Soffietti R, Ruda R, Bradac GB, Schiffer D: PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 1998, 43:1066-1073. doi:10.1097/00006123-199811000-00035.

    Article  CAS  PubMed  Google Scholar 

  39. Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ: Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 2005, 103:802-809. doi:10.1002/cncr.20828.

    Article  PubMed  CAS  Google Scholar 

  40. Mason WP, Krol GS, DeAngelis LM: Low-grade oligodendroglioma responds to chemotherapy. Neurology 1996, 46:203-207.

    CAS  PubMed  Google Scholar 

  41. Lebrun C, Fontaine D, Bourg V, Ramaioli A, Chanalet S, Vandenbos F, Lonjon M, Fauchon F, Paquis P, Frenay M: Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas with PCV chemotherapy. Eur.J.Neurol. 2007, 14:391-398. doi:10.1111/j.1468-1331.2007.01675.x.

    Article  CAS  PubMed  Google Scholar 

  42. Buckner JC, Gesme D, Jr., O’Fallon JR, Hammack JE, Stafford S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG, Jenkins R: Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J.Clin.Oncol. 2003, 21:251-255. doi:10.1200/JCO.2003.06.023.

    Article  CAS  PubMed  Google Scholar 

  43. van den Bent MJ, Chinot O, Boogerd W, Bravo MJ, Taphoorn MJ, Kros JM, van der Rijt CC, Vecht CJ, De Beule N, Baron B: Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann.Oncol. 2003, 14:599-602. doi:10.1093/annonc/mdg157.

    Article  PubMed  Google Scholar 

  44. van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CC, Vecht C, Allgeier A, Gorlia T: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J.Clin.Oncol. 2003, 21:2525-2528. doi:10.1200/JCO.2003.12.015.

    Article  PubMed  CAS  Google Scholar 

  45. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J.Natl.Cancer Inst. 1998, 90:1473-1479. doi:10.1093/jnci/90.19.1473.

    Article  CAS  PubMed  Google Scholar 

  46. Jenkins RB, Curran W, Scott CB, Cairncross G: Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group. Am.J.Clin.Oncol. 2001, 24:506-508. doi:10.1097/00000421-200110000-00018.

    Article  CAS  PubMed  Google Scholar 

  47. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N.Engl.J.Med. 2005, 352:987-996. doi:10.1056/NEJMoa043330.

    Article  CAS  PubMed  Google Scholar 

  48. Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, Sardell S, Traish D, Gonsalves A, Wilkins P, Westbury C: Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann.Oncol. 2003, 14:1715-1721. doi:10.1093/annonc/mdg371.

    Article  CAS  PubMed  Google Scholar 

  49. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, Polivka M, Criniere E, Marie Y, Mokhtari K, Carpentier AF, Laigle F, Simon JM, Cornu P, Broet P, Sanson M, Delattre JY: Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J.Clin.Oncol. 2004, 22:3133-3138. doi:10.1200/JCO.2004.10.169.

    Article  CAS  PubMed  Google Scholar 

  50. Kaloshi G, Benouaich-Amiel A, Diakite F, Taillibert S, Lejeune J, Laigle-Donadey F, Renard MA, Iraqi W, Idbaih A, Paris S, Capelle L, Duffau H, Cornu P, Simon JM, Mokhtari K, Polivka M, Omuro A, Carpentier A, Sanson M, Delattre JY, Hoang-Xuan K: Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 2007, 68:1831-1836. doi:10.1212/01.wnl.0000262034.26310.a2.

    Article  CAS  PubMed  Google Scholar 

  51. Murphy PS, Viviers L, Abson C, Rowland IJ, Brada M, Leach MO, Dzik-Jurasz AS: Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br.J.Cancer 2004, 90:781-786. doi:10.1038/sj.bjc.6601593.

    Article  CAS  PubMed  Google Scholar 

  52. Pouratian N, Gasco J, Sherman JH, Shaffrey ME, Schiff D: Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas. J.Neurooncol. 2007, 82:281-288. doi:10.1007/s11060-006-9280-4.

    Article  CAS  PubMed  Google Scholar 

  53. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006, 66:1258-1260. doi:10.1212/01.wnl.0000208958.29600.87.

    Article  CAS  PubMed  Google Scholar 

  54. Pediatric Brain Tumor Consortium and National Cancer Institute (NCI): Bevacizumab and irinotecan in treating young patients with recurrent, progressive, or refractory glioma, medulloblastoma, ependymoma, or low grade glioma. http://clinicaltrials.gov, 2009. Accessed February 27, 2009

  55. Savage DG, Antman KH: Imatinib mesylate—a new oral targeted therapy. N.Engl.J.Med. 2002, 346:683-693. doi:10.1056/NEJMra013339.

    Article  CAS  PubMed  Google Scholar 

  56. Duke University and Novartis Pharmaceuticals: Phase II imatinib + hydroxyurea in treatment of patients with recurrent/progressive grade II low-grade glioma (LGG). http://clinicaltrials.gov, 2009. Accessed February 27, 2009

  57. UCSF Helen Diller Family Comprehensive Cancer Center and National Cancer Institute (NCI): Everolimus in treating patients with recurrent or progressive low-grade glioma. http://clinicaltrials.gov, 2009. Accessed February 27, 2009

Download references

Author information

Authors and Affiliations

  1. Section of Hematology and Oncology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157, USA

    Jimmy Ruiz MD & Glenn J. Lesser MD

Authors
  1. Jimmy Ruiz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Glenn J. Lesser MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jimmy Ruiz MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ruiz, J., Lesser, G.J. Low-Grade Gliomas. Curr. Treat. Options in Oncol. 10, 231–242 (2009). https://doi.org/10.1007/s11864-009-0096-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-009-0096-2

Search

Navigation